Cirrhosis News and Research

Latest Cirrhosis News and Research

Etiologies of liver cancer are changing and the prognosis is mixed, study says

The primary causes of liver cancer are well known: viral (hepatitis B and C), alcohol and non-alcoholic steatohepatitis (NASH), a condition in which fat builds up in the liver, resulting in chronic inflammation and damage.

7 Jun 2022

Benefits and limitations of non-invasive tests for diagnosing non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent chronic liver disorders worldwide and can sometimes lead to severe conditions like cirrhosis and hepatocellular carcinoma.

2 Jun 2022

Study highlights the need for liver cirrhosis patients to be educated on hepatic venous pressure gradient

Just like the hypertension that people develop when their blood pressure increases, the increase of blood pressure in the main vein that supplies blood to the liver, called the portal vein, is also a dangerous situation.

31 May 2022

NTU scientists discover why NAFLD patients are at higher risk of cardiovascular disease

Patients with non-alcoholic fatty liver disease (NAFLD) are at higher risk of cardiovascular disease, because NAFLD prompts the over-production of a class of proteins that cause inflammation and damage to their blood vessels.

25 May 2022

Study outlines risk factors for autoimmune hepatitis after liver transplant

A multicenter study performed by a large international consortium that includes UT Southwestern has outlined a set of risk factors and outcomes for patients with autoimmune hepatitis (AIH) that recurs after liver transplantation.

20 May 2022

Novel non-invasive method for predicting complications in chronic liver disease

In a recent study, an interdisciplinary research team from MedUni Vienna showed that functional magnetic resonance imaging (fMRI) can be used as a non-invasive method for predicting complications in chronic liver disease.

19 May 2022

Lean people with NAFLD more likely to have cardiovascular disease than those who are overweight

Those with a normal body mass index (BMI) with non-alcoholic fatty liver disease (NAFLD) are more likely to have cardiovascular disease than those who are overweight or living with obesity, according to research selected for presentation at Digestive Disease Week 2022.

13 May 2022

Perceived stigmatization is common among patients with NAFLD, study finds

About seven out of ten patients (69%) who suffer from non-alcoholic fatty liver disease (NAFLD) perceive some stigmatization in their daily life, according to a study led by a team of the University of Barcelona, the Liver and Digestive Diseases Networking Biomedical Research Centre, the Hospital Clínic de Barcelona and the August Pi i Sunyer Biomedical Research Institute.

12 May 2022

Exercise can have a beneficial effect on factors contributing to NAFLD, study shows

Exercise supports the treatment of non-alcoholic fatty liver disease by impacting on several metabolic pathways in the body, a new study from the University of Eastern Finland shows.

3 May 2022

About one in four adults has a liver condition that is a risk factor for heart disease

It is estimated that about one in four adults worldwide has a liver condition that is a risk factor for heart disease, according to a new American Heart Association scientific statement published today in the Association's peer-reviewed journal Arteriosclerosis, Thrombosis, and Vascular Biology.

14 Apr 2022

UCL researchers boost the effectiveness of therapeutic vaccine for chronic HBV

Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.

13 Apr 2022

Modified version of hormone kisspeptin can be used to treat non-alcoholic fatty liver disease

A hormone that triggers puberty and controls fertility in humans might be developed as a treatment for non-alcoholic fatty liver disease, according to new Rutgers research.

7 Apr 2022

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Results from a preclinical study add new evidence that a multi-mineral dietary supplement known as Aquamin could be a simple and effective way to reduce the long-term health consequences of non-alcoholic fatty liver disease.

3 Apr 2022

Siemens Healthineers launches Enhanced Liver Fibrosis (ELF) Test in the U.S.

The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool.

From Siemens Healthineers Laboratory Diagnostics 17 Mar 2022

High-fat diet combined with liquid fructose intake accelerates fat accumulation in the liver

A high-fat diet is not enough to cause short-term fatty liver disease. However, if this diet is combined with the intake of beverages sweetened with liquid fructose, the accumulation of fats in the liver accelerates and hypertriglyceridemia —a cardiovascular risk factor— can appear.

4 Mar 2022

Cirrhosis News and Research

Latest Cirrhosis News and Research

Etiologies of liver cancer are changing and the prognosis is mixed, study says

Benefits and limitations of non-invasive tests for diagnosing non-alcoholic fatty liver disease

Study highlights the need for liver cirrhosis patients to be educated on hepatic venous pressure gradient

NTU scientists discover why NAFLD patients are at higher risk of cardiovascular disease

Study outlines risk factors for autoimmune hepatitis after liver transplant

Novel non-invasive method for predicting complications in chronic liver disease

Lean people with NAFLD more likely to have cardiovascular disease than those who are overweight

Perceived stigmatization is common among patients with NAFLD, study finds

Exercise can have a beneficial effect on factors contributing to NAFLD, study shows

About one in four adults has a liver condition that is a risk factor for heart disease

UCL researchers boost the effectiveness of therapeutic vaccine for chronic HBV

Modified version of hormone kisspeptin can be used to treat non-alcoholic fatty liver disease

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Siemens Healthineers launches Enhanced Liver Fibrosis (ELF) Test in the U.S.

High-fat diet combined with liquid fructose intake accelerates fat accumulation in the liver

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

New signature initiative on increasing alcohol taxes could benefit people’s health, reduce mortality

Discovery could lead to new treatment approach for people with alcohol-associated liver disease

Researchers highlight the extent to which NAFLD and diabetes jointly occur worldwide

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cirrhosis News and Research

Latest Cirrhosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in